A new analysis found the few companies with programs for improving access in poor countries largely fail to report how many patients are being reached.
By Ed Silverman
More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.